Literature DB >> 89099

Epstein-Barr virus-induced membrane antigens: immunochemical characterization of Triton X-100 solubilized viral membrane antigens from EBV-superinfected Raji cells.

L F Qualtiere, G R Pearson.   

Abstract

In an attempt to qualitatively identify the membrane antigen (MA) complex induced by Epstein-Barr virus (EBV) infection of lymphoblastoid cells, superinfected Raji cells were surface labelled with 125I by the lactoperoxidase method and solubilized with Triton X-100, then the 125I-labelled membrane proteins were precipitated by sera containing high antibody titers to MA. Analysis of these immune precipitates on sodium dodecyl sulfate polyacrylamide gel eletrophoresis identified four major EBV-specific membrane proteins with molecular weights (mol. wt) of 280,000, 250,000, 170,000 and 90,000. Sera from patients with Burkitt's lymphoma (BL), nasopharyngeal carcinoma (NPC) and infectious mononucleosis (IM) and from EBV-infected disease-free individuals showed differential patterns of reactivity to these antigens with some sera only recognizing three or less of the antigens. The results from invesigations with these sera also indicated that these major proteins were not related to EBV-induced viral capsid antigens (VCA) or the virus-associated early antigen (EA) complexes as defined by immunofluorescence. Metabolic labelling of EBV-infected Raji cells with [14C]glucosamine, followed by Triton X-100 solubilization and radioimmune precipitation, identified the 280,000, 250,000 and 90,000 components as glycoproteins. The lactoperoxidase-labelled 170,000 molecular weight component was not significantly glycosylated and, therefore, could not be categorized as a glycoprotein on the basis of this study. In addition, a glycoprotein with a mol. wt of 130,000 was identified by this approach which also appeared to be specified by EBV. The results from these investigations, therefore, indicated that the EBV-induced MA complex was composed of four major glycoproteins and one nonglycosylated high mol. wt protein.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 89099     DOI: 10.1002/ijc.2910230612

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  28 in total

Review 1.  Control of viral disease: the development of Epstein-Barr virus vaccines.

Authors:  A J Morgan
Journal:  Springer Semin Immunopathol       Date:  1991

2.  Cleavage of Epstein-Barr virus glycoprotein B is required for full function in cell-cell fusion with both epithelial and B cells.

Authors:  Jessica Sorem; Richard Longnecker
Journal:  J Gen Virol       Date:  2009-03       Impact factor: 3.891

3.  Characterization of the restricted component of Epstein-Barr virus early antigens as a cytoplasmic filamentous protein.

Authors:  J Luka; G Miller; H Jörnvall; G R Pearson
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

4.  The Epstein-Barr virus glycoprotein 110 carboxy-terminal tail domain is essential for lytic virus replication.

Authors:  S K Lee; R Longnecker
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Characterization of a major protein with a molecular weight of 160,000 associated with the viral capsid of Epstein-Barr virus.

Authors:  B Vroman; J Luka; M Rodriguez; G R Pearson
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

6.  Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB.

Authors:  M Gong; T Ooka; T Matsuo; E Kieff
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

7.  Detection by monoclonal antibodies of an early membrane protein induced by Epstein-Barr virus.

Authors:  N Balachandran; J Pittari; L M Hutt-Fletcher
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

8.  Induction of antibodies to the Epstein-Barr virus glycoprotein gp85 with a synthetic peptide corresponding to a sequence in the BXLF2 open reading frame.

Authors:  D E Oba; L M Hutt-Fletcher
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

9.  p105, an Epstein-Barr virus-induced, phosphonoacetic acid-insensitive glycoprotein target of the anti-Epstein-Barr virus immune response.

Authors:  D Casareale; W Jones; T Sairenji; R E Humphreys
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

10.  Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes.

Authors:  J R North; A J Morgan; J L Thompson; M A Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.